DLL3 and small cell lung carcinoma: In this study, we designed a CAR based on an anti-DLL3 SC16 antibody that is effective in various metastatic and orthotopic SCLC models with medium (H82 and SHP-77) and low (H69) surface expression levels of DLL3 (9).